rotate-mobile
Mercoledì, 17 Aprile 2024
Salute

Danish Medicines Council Grants Approval for CSL Behring's Respreeza as Standard Treatment for Severe Alpha-1 Antitrypsin Deficiency Patients



In Evidenza

Potrebbe interessarti

Danish Medicines Council Grants Approval for CSL Behring's Respreeza as Standard Treatment for Severe Alpha-1 Antitrypsin Deficiency Patients

Today è in caricamento